164 related articles for article (PubMed ID: 21895535)
1. Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.
Di WL; Semenova E; Larcher F; Del Rio M; Harper JI; Thrasher AJ; Qasim W
Hum Gene Ther; 2012 Jan; 23(1):83-90. PubMed ID: 21895535
[TBL] [Abstract][Full Text] [Related]
2. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.
Di WL; Larcher F; Semenova E; Talbot GE; Harper JI; Del Rio M; Thrasher AJ; Qasim W
Mol Ther; 2011 Feb; 19(2):408-16. PubMed ID: 20877344
[TBL] [Abstract][Full Text] [Related]
3. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.
Di WL; Mellerio JE; Bernadis C; Harper J; Abdul-Wahab A; Ghani S; Chan L; Martinez-Queipo M; Hara H; McNicol AM; Farzaneh F; McGrath J; Thrasher A; Qasim W
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):182-90. PubMed ID: 24329107
[TBL] [Abstract][Full Text] [Related]
4. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial.
Di WL; Lwin SM; Petrova A; Bernadis C; Syed F; Farzaneh F; Moulding D; Martinez AE; Sebire NJ; Rampling D; Virasami A; Zamiri M; Wang W; Hara H; Kadiyirire T; Abdul-Wahab A; Martinez-Queipo M; Harper JI; McGrath JA; Thrasher AJ; Mellerio JE; Qasim W
Hum Gene Ther; 2019 Sep; 30(9):1067-1078. PubMed ID: 31288584
[TBL] [Abstract][Full Text] [Related]
5.
Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
[TBL] [Abstract][Full Text] [Related]
6. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
7. Phase I study protocol for ex-vivo lentiviral gene therapy for the inherited skin disease, Netherton Syndrome.
Di WL; Mellerio JE; Bernadis C; Harper J; Abdul-Wahab A; Ghani S; Martinez-Queipo M; Hara H; McNicol AM; McGrath J; Thrasher AJ; Qasim W
Hum Gene Ther Clin Dev; 2013 Oct; ():. PubMed ID: 24138501
[TBL] [Abstract][Full Text] [Related]
8. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
9. Regulation of serine protease inhibitor Kazal type-5 (SPINK5) gene expression in the keratinocytes.
Le NA; Katsuyama M; Demura M; Tanii H; Katsuyama H; Saijoh K
Environ Health Prev Med; 2014 Jul; 19(4):307-13. PubMed ID: 24894987
[TBL] [Abstract][Full Text] [Related]
10. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
[TBL] [Abstract][Full Text] [Related]
11. SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing.
Tartaglia-Polcini A; Bonnart C; Micheloni A; Cianfarani F; Andrè A; Zambruno G; Hovnanian A; D'Alessio M
J Invest Dermatol; 2006 Feb; 126(2):315-24. PubMed ID: 16374478
[TBL] [Abstract][Full Text] [Related]
12. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology.
Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH
Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754
[TBL] [Abstract][Full Text] [Related]
14. Exon-Specific U1s Correct SPINK5 Exon 11 Skipping Caused by a Synonymous Substitution that Affects a Bifunctional Splicing Regulatory Element.
Dal Mas A; Fortugno P; Donadon I; Levati L; Castiglia D; Pagani F
Hum Mutat; 2015 May; 36(5):504-12. PubMed ID: 25665175
[TBL] [Abstract][Full Text] [Related]
15. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo.
Herbst F; Ball CR; Tuorto F; Nowrouzi A; Wang W; Zavidij O; Dieter SM; Fessler S; van der Hoeven F; Kloz U; Lyko F; Schmidt M; von Kalle C; Glimm H
Mol Ther; 2012 May; 20(5):1014-21. PubMed ID: 22434137
[TBL] [Abstract][Full Text] [Related]
16. Comèl-Netherton syndrome defined as primary immunodeficiency.
Renner ED; Hartl D; Rylaarsdam S; Young ML; Monaco-Shawver L; Kleiner G; Markert ML; Stiehm ER; Belohradsky BH; Upton MP; Torgerson TR; Orange JS; Ochs HD
J Allergy Clin Immunol; 2009 Sep; 124(3):536-43. PubMed ID: 19683336
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
18. Interplay of Promoter Usage and Intragenic CpG Content: Impact on GFP Reporter Gene Expression.
Krinner S; Heitzer A; Asbach B; Wagner R
Hum Gene Ther; 2015 Dec; 26(12):826-40. PubMed ID: 26414116
[TBL] [Abstract][Full Text] [Related]
19. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.
Di WL; Hennekam RC; Callard RE; Harper JI
Br J Dermatol; 2009 Aug; 161(2):404-12. PubMed ID: 19438860
[TBL] [Abstract][Full Text] [Related]
20. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
Komatsu N; Saijoh K; Jayakumar A; Clayman GL; Tohyama M; Suga Y; Mizuno Y; Tsukamoto K; Taniuchi K; Takehara K; Diamandis EP
J Invest Dermatol; 2008 May; 128(5):1148-59. PubMed ID: 17989726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
